Opus Genetics reports positive data on gene therapies for vision restoration

From GlobeNewswire: 2025-05-15 08:00:00

Opus Genetics presented 12-month results from Phase 1/2 study on OPGx-LCA5 gene therapy at ARVO, showing potential to restore vision. Pediatric cohort ongoing, with initial data expected in Q3 2025. OPGx-BEST1 set for Phase 1/2 trial initiation in Q1 2026. Leading investors provide funding for key milestones. Financial results and corporate update shared.

Opus Genetics reported positive 12-month data for OPGx-LCA5 in treating LCA5, with sustained efficacy in adult patients. Pediatric enrollment ongoing, with early positive results. Plans to expand gene therapy pipeline with BEST-1 program. Near-term data expected from phentolamine eye drop trials. Successful financing secured from healthcare investors.

Opus’s pipeline includes gene therapy assets for IRDs and Phentolamine Ophthalmic Solution 0.75%. OPGx-LCA5 gene therapy shows potential to restore vision for LCA5 patients. OPGx-BEST1 program on track for Phase 1/2 trial in 2025. Successful financing raised with leading healthcare investors. Plans for clinical data readouts in eye drop trials.

Financially, Opus had $41.8 million in cash as of March 31, 2025. License and collaborations revenue increased to $4.4 million. Operating expenses rose due to R&D and administrative costs. Net loss for Q1 2025 was $8.2 million. Future growth drivers include data from pediatric patients, IND filing for OPGx-BEST1, and eye drop trial results.



Read more at GlobeNewswire:: Opus Genetics Announces Financial Results for First Quarter